Andrew Camilli

The long-term goals of my laboratory are to increase our understanding of the life cycles of mucosal pathogens, to develop ways to treat or prevent infections by them, and to help train the next generation of biomedical researchers and teachers. We use two model pathogens in our research, Vibrio cholerae and Streptococcus pneumoniae. V. cholerae is a motile bacterium that maintains a substantial environmental reservoir, and causes endemic and epidemic cholera in many underdeveloped nations. An efficacious vaccine to prevent cholera is lacking. In contrast, S. pneumoniae is a strict human pathogen with no known environmental reservoir. An efficacious vaccine exists that protects against a minority of serotype strains, however S. pneumoniae remains a major cause of mortality.

Our primary research focus is identifying V. cholerae and S. pneumoniae genes and their protein products that are expressed during the infection process and during transmission, and then elucidating their regulation and function. We have chosen this focus because, firstly, bacteria generally express genes only when and where needed, and thus do not readily reveal their pathogenic armament outside of infected tissues. Secondly, detailed knowledge of the behavior of pathogens and the antigens they express during infection and transmission are crucial to development of more effective vaccines, antimicrobials and diagnostics.

Our studies have revealed a number of important findings concerning the life cycle of V. cholerae and ways to prevent infection. These include the discoveries that V. cholerae exits humans in rice water stool (see figure) in a heightened state of infectivity, but that lytic bacteriophage, commonly present in cholera rice water stools, can antagonize transmission and subsequent infection. We hypothesize that the hyperinfectious state of V. cholerae aids in transmission and therefore the rapid spread of cholera during outbreaks. In contrast, we propose that lytic bacteriophages function to moderate infections and to reduce transmission. We are currently developing phage cocktails for oral ingestion to prevent cholera infections in people at high risk.